[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sglt-2-inhibitors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sglt-2-inhibitors":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100615461","phase-4-effect-of-empagliflozin-on-inflammation-100615461",false,"NCT07292909","Effect of Empagliflozin on Inflammation","Randomized Trial to Evaluate the Anti-inflammatory Effects of Empagliflozin Following PCI","EMPANTINFLAM","Inclusion Criteria:\n\n* • Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery\n\nExclusion Criteria:\n\n* • Patients who have been taking an SGLT-2 inhibitor during the last month\n\n  * Patients who are receiving any anti-inflammatory medication: immunosuppressor, steroids, NSAID…\n  * Patients who have underlying inflammatory conditions such as rheumatic arthritis, infection, active malignancy\n  * Patients with an acute coronary syndrome within the last month\n  * Intervention on a restenotic lesion or lesion in a saphenous vein graft\n  * Creatinine clearance less than 30 mL\u002Fmin\n  * Patients who are treated with devices other than balloons and stents (lithotripsy, rotational atherectomy…)","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood.\n\nHe hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect.\n\nTo document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent will develop inflammation following stenting. This is documenting by a higher level of C-Reactive Protein 24 hours after the procedure.\n\nPatients who will participate in the study, will receive empagliflozin or a placebo tablet for 3 days prior to the revascularisation procedure. CRP and other inflammatory markers will be measured before intervention and 24 hours later. The goal is to demonstrate a lower rise in CRP following intervention in patients treated with empagliflozin vs. those who have received a placebo.",[27,28,29,30],"CAD - Coronary Artery Disease","Inflamation","PCI","SGLT 2 Inhibitors",[32,33,34],"CAD","inflammation","SGLT2 inhibitors","RECRUITING","2025-12-06",{"date":38,"type":39},"2025-12-18","ACTUAL",{"date":41,"type":39},"2025-09-01",{"date":43,"type":21},"2027-09-30",{"name":45,"class":46},"Hotel Dieu de France Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100607253","effect-of-sodium-glucose-co-transporter-2-inhibitors-on-left-atrial-remodeling-in-diabetic-patients-100607253","NCT07186153","Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients","Inclusion Criteria:\n\n* Diagnosed T2DM on antidiabetic medication not including SGLT2 inhibitors.\n* HbA1c ≤ 7%.\n* Age 40-75 years.\n* Sinus rhythm.\n* Informed consent obtained\n\nExclusion Criteria:\n\n* History of atrial fibrillation or flutter.\n* Patients treated with SGLT2 inhibitors.\n* Severe mitral valve regurgitation or stenosis.\n* Previous myocardial infarction.\n* Previous percutaneous coronary intervention(PCI) or coronary artery bypass grafting (CABG).\n* LV Ejection fraction \\\u003C50% .\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Uncontrolled hypertension (BP \\> 160\u002F100 mmHg)\n* Inadequate echocardiographic windows or incomplete data","40 Years","75 Years",{"count":20,"type":21},"OBSERVATIONAL","To evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) before and after treatment with SGLT2 inhibitors",[30],[61],"left atrial remodelling","NOT_YET_RECRUITING","2025-09-15",{"date":65,"type":39},"2025-09-22",{"date":67,"type":21},"2025-10-01",{"date":69,"type":21},"2026-11-01",{"name":71,"class":46},"Assiut University","SGLT-2 Inhibitors"]